
|Articles|August 1, 2003
Melanoma Survival Rate and Vitiligo
Author(s)Walter Alexander
Chicago - Among patients receiving a novel immune-based maintenance biotherapy regimen (mBT) for metastatic melanoma, those who developed vitiligo had longer median survival.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Karan Lal, DO, Shares Evolving Perspective on GLP-1 Agonists in Dermatology at SDPA Fall 2025
2
Dermatology Times Hosts 2025 Horizons in Advanced Practice Meeting
3
Nemolizumab Demonstrates Strong Efficacy in PN
4
Q&A: Treating Vitiligo in Difficult Sites Requires Patience and Precision
5



















